601089 福元医药
交易中 12-18 14:45:52
资讯
新帖
简况
福元医药：华福证券、安信基金等多家机构于12月10日调研我司
证券之星 · 12-11
福元医药：华福证券、安信基金等多家机构于12月10日调研我司
【机构调研记录】银华基金调研福元医药、航天南湖
证券之星 · 12-08
【机构调研记录】银华基金调研福元医药、航天南湖
福元医药(601089.SH)：酮洛芬凝胶贴膏获得药物临床试验批准通知书
智通财经 · 11-27
福元医药(601089.SH)：酮洛芬凝胶贴膏获得药物临床试验批准通知书
异动快报：福元医药（601089）11月26日9点58分触及涨停板
证券之星 · 11-26
异动快报：福元医药（601089）11月26日9点58分触及涨停板
【机构调研记录】国联基金调研福元医药
证券之星 · 11-24
【机构调研记录】国联基金调研福元医药
【机构调研记录】兴业基金调研福元医药
证券之星 · 11-24
【机构调研记录】兴业基金调研福元医药
每周股票复盘：福元医药（601089）拟推股权激励计划
证券之星 · 11-23
每周股票复盘：福元医药（601089）拟推股权激励计划
福元医药：中信证券、东吴基金等多家机构于11月19日调研我司
证券之星 · 11-21
福元医药：中信证券、东吴基金等多家机构于11月19日调研我司
每周股票复盘：福元医药（601089）依折麦布阿托伐他汀钙片获批
证券之星 · 11-16
每周股票复盘：福元医药（601089）依折麦布阿托伐他汀钙片获批
福元医药（601089）披露股东大会决议公告，11月14日股价上涨2.09%
证券之星 · 11-14
福元医药（601089）披露股东大会决议公告，11月14日股价上涨2.09%
福元医药(601089.SH)：依折麦布阿托伐他汀钙片(Ⅰ)获得药品注册证书
智通财经 · 11-11
福元医药(601089.SH)：依折麦布阿托伐他汀钙片(Ⅰ)获得药品注册证书
福元医药：公司会在定期报告中依据相关法律法规披露股东人数以保证所有投资者平等获悉公司信息
证券日报网 · 11-05
福元医药：公司会在定期报告中依据相关法律法规披露股东人数以保证所有投资者平等获悉公司信息
每周股票复盘：福元医药（601089）Q3净利降2.59%，股东户数减少3.39%
证券之星 · 11-02
每周股票复盘：福元医药（601089）Q3净利降2.59%，股东户数减少3.39%
福元医药（601089）披露取消监事会、增加董事会席位及修订《公司章程》公告，10月30日股价下跌0.91%
证券之星 · 10-30
福元医药（601089）披露取消监事会、增加董事会席位及修订《公司章程》公告，10月30日股价下跌0.91%
图解福元医药三季报：第三季度单季净利润同比下降2.59%
证券之星 · 10-29
图解福元医药三季报：第三季度单季净利润同比下降2.59%
每周股票复盘：福元医药（601089）地屈孕酮片获注册证书
证券之星 · 10-26
每周股票复盘：福元医药（601089）地屈孕酮片获注册证书
福元医药(601089.SH)取得克立硼罗原料药上市申请批准通知书
智通财经 · 10-24
福元医药(601089.SH)取得克立硼罗原料药上市申请批准通知书
福元医药(601089.SH)：地屈孕酮片获药品注册证书
智通财经网 · 10-21
福元医药(601089.SH)：地屈孕酮片获药品注册证书
福元医药(601089.SH)：坎地沙坦酯氢氯噻嗪片(Ⅱ)获得药品注册证书
智通财经 · 09-29
福元医药(601089.SH)：坎地沙坦酯氢氯噻嗪片(Ⅱ)获得药品注册证书
每周股票复盘：福元医药（601089）FY101临床进展达预期
证券之星 · 09-21
每周股票复盘：福元医药（601089）FY101临床进展达预期
公司概况
公司名称：
北京福元医药股份有限公司
所属行业：
医药制造业
上市日期：
2022-06-30
主营业务：
北京福元医药股份有限公司的主营业务是药品制剂及医疗器械的研发、生产和销售。公司的主要产品是心血管系统类、慢性肾病类、皮肤病类、消化系统类、糖尿病类、精神神经系统类、妇科类、一次性使用吸氧管。公司已入选北京医药产业跨越发展工程G20企业，荣列中国药品研发综合实力百强榜。
发行价格：
14.62
{"stockData":{"symbol":"601089","market":"SH","secType":"STK","nameCN":"福元医药","latestPrice":23,"timestamp":1766040352000,"preClose":23.21,"halted":0,"volume":2502300,"delay":0,"changeRate":-0.009,"floatShares":480000000,"shares":480000000,"eps":0.9648,"marketStatus":"交易中","change":-0.21,"latestTime":"12-18 14:45:52","open":23.16,"high":23.26,"low":22.84,"amount":57597500,"amplitude":0.0181,"askPrice":23,"askSize":11,"bidPrice":22.98,"bidSize":12,"shortable":0,"etf":0,"ttmEps":0.9648,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1766041200000},"marketStatusCode":2,"adr":0,"adjPreClose":23.21,"symbolType":"stock","openAndCloseTimeList":[[1766021400000,1766028600000],[1766034000000,1766041200000]],"highLimit":25.53,"lowLimit":20.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":480000000,"isCdr":false,"pbRate":3.02,"roa":"--","peRate":23.839138,"roe":"10.35%","epsLYR":1.04,"committee":-0.051414,"marketValue":11040000000,"turnoverRate":0.0052,"status":1,"floatMarketCap":11040000000},"requestUrl":"/m/hq/s/601089/wiki","defaultTab":"wiki","newsList":[{"id":"2590859410","title":"福元医药：华福证券、安信基金等多家机构于12月10日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2590859410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590859410?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:03","pubTimestamp":1765447402,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月11日福元医药发布公告称华福证券陈铁林、安信基金池陈森、中信医药王凯旋、平安证券韩盟盟 倪亦道 曹艳凯、平安养老蔡晟 陶歆蔚、华源证券刘闯 孙洁玲、大成基金杨挺 陈泉龙 阳洪宇 徐雄晖 李煜 王晶晶于2025年12月10日调研我司。漷县基地整体规划产能为100亿片，一期投产后将逐步释放产能，全部建成达产后可充分满足公司未来销售增长需求，为公司长期发展提供有力的产能保障。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100030011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239","161027"],"gpt_icon":0},{"id":"2589801795","title":"【机构调研记录】银华基金调研福元医药、航天南湖","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589801795?lang=zh_cn&edition=full","pubTime":"2025-12-08 08:01","pubTimestamp":1765152098,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月5日披露的机构调研信息，银华基金近期对2家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司坚持“临床急需、仿创结合”策略，依托化学合成、口服固体制剂等平台，形成仿制药与创新药双轮驱动。仿制药聚焦心血管、神经、皮肤等领域，已有15个首仿产品，18个品种中标集采。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800000294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688552","601089","BK0239","BK0214"],"gpt_icon":0},{"id":"2586212006","title":"福元医药(601089.SH)：酮洛芬凝胶贴膏获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586212006","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586212006?lang=zh_cn&edition=full","pubTime":"2025-11-27 15:34","pubTimestamp":1764228897,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司全资子公司福元药业有限公司(简称“福元药业”)收到了国家药品监督管理局核准签发的酮洛芬凝胶贴膏的《药物临床试验批准通知书》。福元药业申请药物临床试验的酮洛芬凝胶贴膏，适应症为适用于下列疾病和症状的镇痛及消炎：骨关节炎、肩周炎、肌腱及肌腱炎、肌腱周围炎、肱骨外上髁炎(网球肘等)、肌肉痛、外伤后肿胀及疼痛。给药途径为局部，注册分类属化学药品3类。截至目前，福元药业对本品已投入研发费用约人民币396.76万元(未经审计)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374405.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2586289340","title":"异动快报：福元医药（601089）11月26日9点58分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2586289340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586289340?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:01","pubTimestamp":1764122468,"startTime":"0","endTime":"0","summary":"证券之星11月26日盘中消息，9点58分福元医药触及涨停板。其所属行业化学制药目前上涨。领涨股为康芝药业。该股为创新药，减肥药，医药概念热股，当日创新药概念上涨2.2%，减肥药概念上涨2.07%，医药概念上涨1.95%。11月25日的资金流向数据方面，主力资金净流出529.35万元，占总成交额4.76%，游资资金净流出542.59万元，占总成交额4.88%，散户资金净流入1071.95万元，占总成交额9.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600007211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2585435435","title":"【机构调研记录】国联基金调研福元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2585435435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585435435?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:01","pubTimestamp":1763942495,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月21日披露的机构调研信息，国联基金近期对1家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司截至2024年底研发人员达415人，FY101注射液正进行一期临床试验，预计明年启动二期。国联基金成立于2013年，截至目前，资产管理规模1486.77亿元，排名47/211；资产管理规模1227.98亿元，排名43/211；管理公募基金数187只，排名37/211；旗下公募基金经理28人，排名48/211。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400000229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2585455435","title":"【机构调研记录】兴业基金调研福元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2585455435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585455435?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:01","pubTimestamp":1763942483,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月21日披露的机构调研信息，兴业基金近期对1家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司截至2024年底研发人员达415人，FY101注射液正进行一期临床试验，预计明年启动二期。兴业基金成立于2013年，截至目前，资产管理规模4171.34亿元，排名27/211；资产管理规模2452.86亿元，排名24/211；管理公募基金数207只，排名34/211；旗下公募基金经理28人，排名48/211。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400000213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2585106602","title":"每周股票复盘：福元医药（601089）拟推股权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2585106602","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585106602?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:35","pubTimestamp":1763843712,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，福元医药报收于22.01元，较上周的23.9元下跌7.91%。本周，福元医药11月17日盘中最高价报23.9元。福元医药当前最新总市值105.65亿元，在化学制药板块市值排名50/151，在两市A股市值排名1707/5167。FY101注射液正按计划开展一期临床试验，当前结果符合预期，预计将于明年启动二期临床试验。公司于2025年2月4日完成股份回购，累计回购12,000,000股，约占总股本2.50%，将用于股权激励计划，具体实施将结合战略规划适时推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2585112241","title":"福元医药：中信证券、东吴基金等多家机构于11月19日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2585112241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585112241?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:26","pubTimestamp":1763720789,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年11月21日福元医药发布公告称中信证券彭康 唐嘉奕 盛黎阳、东吴基金吴佳歆、平安资管林启姜、华商基金李海伟、方正证券李霁阳 茹帅 吕行之、中银基金王方舟、招商基金李稼存 周雨婷、鹏华基金王子建 蔡春根、国联基金刘柏川、信达澳亚杨柯、兴业基金解婕于2025年11月19日调研我司。福元医药主营业务：药品制剂及医疗器械的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100029412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","LU2495084118.USD","BK0196","BK0276","LU1720050803.USD","LU1064130708.USD","BK0028","600030","LU1255011170.USD","LU1997244956.HKD","BK0183","06030","LU1328615791.USD","BK1564","601089","LU1997245094.SGD","LU1997245177.USD","BK1516","BK0012","LU0405327148.USD","BK1521","BK0188","BK0239","BK1147","LU1794554557.SGD","LU1655091616.SGD","LU0405327494.USD","LU2289578879.USD"],"gpt_icon":0},{"id":"2583989654","title":"每周股票复盘：福元医药（601089）依折麦布阿托伐他汀钙片获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2583989654","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583989654?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:45","pubTimestamp":1763239511,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，福元医药报收于23.9元，较上周的21.77元上涨9.78%。本周，福元医药11月14日盘中最高价报24.67元。公司公告汇总北京福元医药股份有限公司近日收到国家药品监督管理局颁发的依折麦布阿托伐他汀钙片（Ⅰ）药品注册证书，批准该药品生产。会议应表决董事9名，实际表决9名，各项议案均获全票通过。子公司福元药业将投资32,320.79万元实施该项目，计划于2028年4月完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2583831507","title":"福元医药（601089）披露股东大会决议公告，11月14日股价上涨2.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583831507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583831507?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:57","pubTimestamp":1763132240,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，福元医药报收于23.9元，较前一交易日上涨2.09%，最新总市值为114.72亿元。该股当日开盘23.3元，最高24.67元，最低23.18元，成交额达3.28亿元，换手率为2.84%。近日，福元医药发布2025年第二次临时股东大会决议公告。所有议案均获通过，无否决议案。会议召集召开程序合法，表决结果有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2582755359","title":"福元医药(601089.SH)：依折麦布阿托伐他汀钙片(Ⅰ)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582755359","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582755359?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:50","pubTimestamp":1762851013,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司收到了国家药品监督管理局(简称“国家药监局”)颁发的依折麦布阿托伐他汀钙片(Ⅰ)(规格：每片含依折麦布10mg与阿托伐他汀钙10mg(按C₃₃H₃₅FN₂O₅计))《药品注册证书》(证书编号：2025S03344)，批准该药品生产。依折麦布阿托伐他汀钙片(Ⅰ)由Organon研制，最早于2013年5月获FDA批准上市，2023年9月，经国家药品监督管理局批准，依折麦布阿托伐他汀钙片(Ⅰ)在中国上市，本品用于高胆固醇血症和纯合子型家族性高胆固醇血症(HoFH)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)：依折麦布阿托伐他汀钙片(Ⅰ)获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2581735757","title":"福元医药：公司会在定期报告中依据相关法律法规披露股东人数以保证所有投资者平等获悉公司信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2581735757","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581735757?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:39","pubTimestamp":1762349940,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n证券日报网讯福元医药11月5日在互动平台回答投资者提问时表示，为保障信息披露的公平原则，公司会在定期报告中依据相关法律法规披露股东人数以保证所有投资者平等获悉公司信息。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkiip4141795.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkiip4141795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2580912472","title":"每周股票复盘：福元医药（601089）Q3净利降2.59%，股东户数减少3.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580912472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580912472?lang=zh_cn&edition=full","pubTime":"2025-11-02 06:46","pubTimestamp":1762037170,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，福元医药报收于23.06元，较上周的22.04元上涨4.63%。本周，福元医药10月31日盘中最高价报23.38元。股本股东变化截至2025年9月30日，福元医药股东户数为22,691户，较6月30日减少796户，减幅3.39%。业绩披露要点2025年前三季度，福元医药实现营收25.21亿元，同比下降1.04%；归母净利润3.75亿元，同比下降6.39%；扣非净利润3.62亿元，同比下降4.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2579678119","title":"福元医药（601089）披露取消监事会、增加董事会席位及修订《公司章程》公告，10月30日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579678119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579678119?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:17","pubTimestamp":1761819431,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，福元医药报收于21.81元，较前一交易日下跌0.91%，最新总市值为104.69亿元。该股当日开盘22.1元，最高22.1元，最低21.68元，成交额达6993.81万元，换手率为0.67%。同日，福元医药发布公告，宣布拟取消监事会，其职权由董事会审计委员会行使，并废止《监事会议事规则》。公司董事会席位拟由8名增至9名，其中新增1名职工代表董事，独立董事保持3名不变。审计委员会将行使监事会的职权，股东会可授权董事会决定特定股票发行事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000036446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2579903457","title":"图解福元医药三季报：第三季度单季净利润同比下降2.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579903457","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579903457?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:16","pubTimestamp":1761740182,"startTime":"0","endTime":"0","summary":"证券之星消息，福元医药2025年三季报显示，前三季度公司主营收入25.21亿元，同比下降1.04%；归母净利润3.75亿元，同比下降6.39%；扣非净利润3.62亿元，同比下降4.85%；其中2025年第三季度，公司单季度主营收入8.87亿元，同比下降0.55%；单季度归母净利润1.07亿元，同比下降2.59%；单季度扣非净利润1.04亿元，同比下降1.8%；负债率22.82%，投资收益1555.93万元，财务费用-444.92万元，毛利率65.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900041380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089"],"gpt_icon":0},{"id":"2578049105","title":"每周股票复盘：福元医药（601089）地屈孕酮片获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2578049105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578049105?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:22","pubTimestamp":1761416532,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，福元医药报收于22.04元，较上周的23.35元下跌5.61%。本周，福元医药10月22日盘中最高价报23.7元。地屈孕酮片用于治疗内源性孕酮不足引起的疾病及辅助生殖技术中的黄体支持。2024年中国三大终端六大市场地屈孕酮片销售额约25.70亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2577560787","title":"福元医药(601089.SH)取得克立硼罗原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2577560787","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577560787?lang=zh_cn&edition=full","pubTime":"2025-10-24 15:38","pubTimestamp":1761291529,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的克立硼罗原料药《化学原料药上市申请批准通知书》。克立硼罗适用于2岁及以上轻度至中度特应性皮炎患者的局部外用治疗。公司本次取得克立硼罗原料药《化学原料药上市申请批准通知书》，将进一步丰富公司产品线，促进公司持续、稳定、健康地发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2577842818","title":"福元医药(601089.SH)：地屈孕酮片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2577842818","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577842818?lang=zh_cn&edition=full","pubTime":"2025-10-21 16:06","pubTimestamp":1761033975,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)公告，公司全资子公司浙江爱生药业有限公司(简称“浙江爱生”)收到了国家药品监督管理局颁发的地屈孕酮片(规格：10mg)《药品注册证书》，批准该药品生产。地屈孕酮是一种口服可吸收的合成孕激素。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)：地屈孕酮片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2571807727","title":"福元医药(601089.SH)：坎地沙坦酯氢氯噻嗪片(Ⅱ)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571807727","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571807727?lang=zh_cn&edition=full","pubTime":"2025-09-29 16:06","pubTimestamp":1759133175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药 发布公告，近日，公司收到了国家药品监督管理局颁发的坎地沙坦酯氢氯噻嗪片(Ⅱ)《药品注册证书》，批准该药品生产。目前原研厂家的坎地沙坦酯氢氯噻嗪片尚未在中国上市。本品不适用于高血压的初始治疗，适用于单用坎地沙坦酯或氢氯噻嗪不能有效控制血压的成年人原发性高血压，或两药联合用药同剂量的替代治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)：坎地沙坦酯氢氯噻嗪片(Ⅱ)获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2569245619","title":"每周股票复盘：福元医药（601089）FY101临床进展达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2569245619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569245619?lang=zh_cn&edition=full","pubTime":"2025-09-21 03:11","pubTimestamp":1758395470,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，福元医药报收于23.08元，较上周的23.62元下跌2.29%。本周，福元医药9月18日盘中最高价报24.35元。福元医药当前最新总市值110.78亿元，在化学制药板块市值排名49/150，在两市A股市值排名1702/5153。FY101 I期临床正按计划推进，目前临床效果达到公司预期。当前临床仅在国内开展。公司已于2025年2月4日完成股份回购，累计回购12,000,000股，占比约2.50%。公司称将统筹资金规划，平衡研发投入与业绩要求，保障项目稳步推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100000669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766040361023,"stockEarnings":[{"period":"1week","weight":-0.0652},{"period":"1month","weight":-0.0051},{"period":"3month","weight":-0.0161},{"period":"6month","weight":0.2412},{"period":"1year","weight":0.5241},{"period":"ytd","weight":0.4946}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京福元医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22691人(较上一季度减少3.39%)","perCapita":"21153股","listingDate":"2022-06-30","address":"北京市通州区通州工业开发区广源东街8号","registeredCapital":"48000万元","survey":" 北京福元医药股份有限公司的主营业务是药品制剂及医疗器械的研发、生产和销售。公司的主要产品是心血管系统类、慢性肾病类、皮肤病类、消化系统类、糖尿病类、精神神经系统类、妇科类、一次性使用吸氧管。公司已入选北京医药产业跨越发展工程G20企业，荣列中国药品研发综合实力百强榜。","listedPrice":14.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福元医药,601089,福元医药股票,福元医药股票老虎,福元医药股票老虎国际,福元医药行情,福元医药股票行情,福元医药股价,福元医药股市,福元医药股票价格,福元医药股票交易,福元医药股票购买,福元医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}